Volume 97, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Meglumine Antimoniate (MA), administered intramuscularly for 21 continuous days is the recommended treatment of leishmaniases in Ecuador. However, because of its toxicity and requirement for intramuscular injections, treatment is frequently abandoned before completion. In addition, therapeutic failure and reactivation are not uncommon. Here we evaluate the efficacy and safety of MA administered intralesionally (IL) in leishmaniasis recidiva cutis (LRC). LRC is a special clinical variant of cutaneous leishmaniasis, characterized by reactivation at the edges of a primary cured lesion, presenting with active papules around the scar. Twenty-one patients were included in the study. All were diagnosed parasitologically by one of three diagnostic methods (smear, culture, and Leishmanin skin test). Each patient received MA intralesionally weekly for 4 weeks. Each papule was infiltrated until complete saturation. On average, patients received 1 mL of MA per administration. The criterion of cure was the complete resolution of the papules. Follow up was performed at 30, 90, and 180 days after treatment. At day 30 after treatment, 19 (90.5%) of 21 patients were clinically cured. The two patients, who did not heal by the fourth application, were cured on the seventh and eighth dose, achieving a clinical cure of 100% without subsequent reactivation. Mild to moderate local pain during infiltration was the only adverse reaction experienced by 81% of patients. In one case, subsequent infiltrations were discontinued because of a local allergic reaction. Complete compliance of patients to treatment and the small volume of drug administered make this method of administering MA an effective, safe, and inexpensive alternative. Consequently, IL could replace intramuscular administration in the treatment of LRC in Ecuador.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Word Health Organization (WHO), 2010. Control of the Leishmaniases: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases. WHO technical report series no. 949. Geneva, Switzerland: Word Health Organization. Available at: http://www.who.int/neglected_diseases/integrated_media/integrated_media_2010_leishmaniasis_2/en/. Accessed March 21, 2017.
  2. Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, Lapujade O, Buffet P, Alvar J, , 2013. Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis 7: e2130.[Crossref] [Google Scholar]
  3. Armijos RX, Weigel MM, Calvopina M, Mancheno M, Rodriguez R, , 2004. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for new world cutaneous leishmaniasis. Acta Trop 91: 153160.[Crossref] [Google Scholar]
  4. Organización Panamericana de la Salud (OPS), 2013. Leishmaniasis en las Américas: Recomendaciones para el Tratamiento. Washington, DC: Organización Panamericana de la Salud, 143. Available at: http://iris.paho.org/xmlui/handle/123456789/7704. Accessed March 21, 2017.
  5. Calvopina M, Armijos RX, Hashiguchi Y, , 2004. Epidemiology of leishmaniasis in Ecuador: current status of knowledge—a review. Mem Inst Oswaldo Cruz 99: 663672.[Crossref] [Google Scholar]
  6. Calvopina M, Loor R, Lara F, Zambrano P, Hashiguchi Y, , 2012. Prevalencia y formas clínicas de las leishmaniasis en el noroccidente de la provincia de Pichincha – Ecuador. Rev Fac Cien Med (Quito) 37: 3138. [Google Scholar]
  7. Calvopina M, Gomez EA, Uezato H, Kato H, Nonaka S, Hashiguchi Y, , 2005. Atypical clinical variants in new world cutaneous leishmaniasis: disseminated, erysipeloid, and recidiva cutis due to Leishmania (V.) panamensis . Am J Trop Med Hyg 73: 281284. [Google Scholar]
  8. Calvopina M, Kato H, Hashiguchi Y, , 2013. Leishmaniasis recidiva cutis and its topical treatment in Ecuador. Trop Med Health 41: 9394.[Crossref] [Google Scholar]
  9. Calvopina M, Uezato H, Gomez EA, Korenaga M, Nonaka S, Hashiguchi Y, , 2006. Leishmaniasis recidiva cutis due to Leishmania (Viannia) panamensis in subtropical Ecuador: isoenzymatic characterization. Int J Dermatol 45: 116120.[Crossref] [Google Scholar]
  10. Calvopina M, 2006. Leishmania isoenzyme polymorphisms in Ecuador: relationships with geographic distribution and clinical presentation. BMC Infect Dis 6: e139.[Crossref] [Google Scholar]
  11. Kato H, Gomez EA, Martini-Robles L, Muzzio J, Velez L, Calvopina M, Romero-Alvarez D, Mimori T, Uezato H, Hashiguchi Y, , 2016. Geographic distribution of Leishmania species in Ecuador based on the Cytochrome B gene sequence analysis. PLoS Negl Trop Dis 10: e0004844.[Crossref] [Google Scholar]
  12. Guderian RH, Chico ME, Rogers MD, Pattishall KM, Grogl M, Berman JD, , 1991. Placebo controlled treatment of Ecuadorian cutaneous leishmaniasis. Am J Trop Med Hyg 45: 9297.[Crossref] [Google Scholar]
  13. Calvopina M, Martinez L, Hashiguchi Y, , 2013. Cutaneous leishmaniasis “Chiclero’s Ulcer” in subtropical Ecuador. Am J Trop Med Hyg 89: 195196.[Crossref] [Google Scholar]
  14. Armijos RX, Weigel MM, Izurieta R, Racines J, Zurita C, Herrera W, Vega M, , 1997. The epidemiology of cutaneous leishmaniasis in subtropical Ecuador. Trop Med Int Health 2: 140152.[Crossref] [Google Scholar]
  15. Soto J, 2013. Intralesional antimony for single lesions of Bolivian cutaneous leishmaniasis. Clin Infect Dis 56: 12551260.[Crossref] [Google Scholar]
  16. Soto J, Paz D, Rivero D, Soto P, Quispe J, Toledo J, Berman J, , 2016. Intralesional pentamidine: a novel therapy for single lesions of Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 94: 852856.[Crossref] [Google Scholar]
  17. Oliveira-Neto MP, Schubach A, Mattos M, da Costa SC, Pirmez C, , 1997. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazilian area of Leishmania (V.) braziliensis transmission. Int J Dermatol 36: 463468.[Crossref] [Google Scholar]
  18. Vasconcellos EC, 2012. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006). Am J Trop Med Hyg 87: 257260.[Crossref] [Google Scholar]
  19. Silva RE, Toledo A, Senna MC, Rabello A, Cota G, , 2016. Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre. Mem Inst Oswaldo Cruz 111: 512516.[Crossref] [Google Scholar]
  20. The Medical Letter, Inc., 2007. On Drugs and Therapeutics. Drugs for Parasitic Infections, 1st edition. New Rochelle, NY: The Medical Letter, Inc.
  21. Ferreira-Vasconcellos EC, Pimentel MI, Valete-Rosalino CM, Madeira MF, Schubach AO, , 2014. Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate. Rev Inst Med Trop Sao Paulo 56: 361362.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 28 Apr 2017
  • Accepted : 30 Jun 2017
  • Published online : 05 Sep 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error